Inactive Instrument

News PHOX BIOT26 Nasdaq

Equities

PBAXU

US71902K2042

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes	04-30	AQ
PHOX BIOT26 : CERo Therapeutics Investor Presentation	04-25	PU
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-02	CI
Top Premarket Decliners	03-11	MT
Top Premarket Gainers	03-08	MT
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients	03-07	BU
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	03-07	CI
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	02-22	CI
Top Premarket Decliners	02-20	MT
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	02-15	MT
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	02-15	CI
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	02-15	CI
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	02-15	CI
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination	02-14	BU
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index	02-13	CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	02-13	CI
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding	02-13	CI
Phoenix Biotech Acquisition Corp. Sinks 15% in Premarket Activity After Plunging 42% in Wednesday's Regular Trading	02-08	MT
Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC	02-04	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PHOX BIOT26 Nasdaq

Equities

PBAXU

US71902K2042

Summary

Filters